Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1174

Cusatuzumab

Home » Cusatuzumab

Background of Cusatuzumab

CD70, a tumor necrosis factor receptor ligand, is a very promising target due to its consistent expression on LSC and AML blasts. In AML, the binding of CD70 to its receptor, CD27, on LSC and subsequent downstream signaling activates gene-expression profiles that promote LSC proliferation, reduce differentiation, and lead to release of soluble CD27. Cusatuzumab (ARGX-110) is a high-affinity, anti-CD70 monoclonal antibody that blocks CD70/CD27 signaling, leading to inhibition of LSC proliferation, a reduction in leukemic blast cells, blockade of regulatory T-cell survival (preventing tumor immune escape), and restoration of normal myeloid differentiation.

Specifications

Catalog Number:
KB-1174
Antibody Name:
Cusatuzumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
CD70
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Riether C, Schürch CM, Bührer ED, et al.. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359-380.
  2. Silence K, Dreier T, Moshir M, et al.. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523-532.